For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenues | - | 0 | ||
| Research and development | 187,808 | 191,608 | ||
| General and administrative | 527,466 | 556,467 | ||
| Total operating expenses | 715,274 | 748,075 | ||
| Loss from operations | -715,274 | -748,075 | ||
| Change in fair value of warrant liability | -1,212 | -902 | ||
| Interest income | 47,325 | 6,654 | ||
| Total other income | 48,537 | 7,556 | ||
| Net loss | -666,737 | -740,519 | ||
| Net loss attributable to common stockholders | -666,737 | - | ||
| Loss per share - basic | -0.37 | -1.33 | ||
| Loss per share - diluted | -0.37 | -1.33 | ||
| Weighted average shares outstanding - basic | 1,795,097 | 557,787 | ||
| Weighted average shares outstanding - diluted | 1,795,097 | 557,787 | ||
Bone Biologics Corp (BBLGW)
Bone Biologics Corp (BBLGW)